Sentences with phrase «target particular proteins»

Recent advances in the understanding of cancer have led to more personalized therapies, such as drugs that target particular proteins and tests that analyze gene expression patterns in tumors to predict a patient's response to therapy.

Walter Fiers discovered that targeting a particular protein segment on the influenza virus might just do the trick

Not exact matches

«In particular, we target regions with growing middle classes, high discretionary spending and an increased desire for healthier protein options,» said Jeff Duffin.

In particular, he has focused on targeting the gene coding for flagellin protein b, or flaB, which has proved to be quite distinct from one genospecies to the next.

The team set out to find antibodies tuned to a particular target: a part of Zika's envelope protein, which the virus needs to launch an attack.

With their new fruit fly research model, the UNC researchers altered the histone gene so that this particular enzyme could not modify its histone protein target.

Cancer - causing proteins that have already been successfully targeted with drugs tended to have particular «social» characteristics that differ from non-cancer proteins — suggesting that previously unexplored cancer proteins with similar characteristics could also make good drug targets.

«The ability to control the functional states of opioid receptors is of particular interest because they belong to the large family of so - called G - protein - coupled transmembrane receptors (GPCRs), which make up a large fraction of the proteins targeted by pharmaceutical agents,» says Matthias Schönberger, first author of the new study.

«New treatment targets cancers with particular genetic signature: Mutations in gene SETD2 make cancer cells vulnerable to drug inhibiting the protein WEE1.»

«Identifying a cancer driver is crucial for cancer treatment because it allows the use of targeted therapies, which have less side - effects than conventional chemotherapy drugs, against a particular protein,» said Kurokawa.

To narrow down the number of chemical compounds that could be potential drug candidates, scientists utilize computer models that can predict how a particular chemical compound might interact with a biological target of interest — for example, a key protein that might be involved with a disease process.

The auto - reactive B cells produced autoantibodies that mistakenly targeted proteins within their own body, in particular targeting immune inflammatory molecules called interferons and interleukins.

During the early years of my PhD studies, I was very fascinated by the exciting discoveries in the field of signal transduction, in particular how receptor tyrosine kinases are activated to transmit their signals and how protein complexes are formed through defined protein folds (domains) interacting with specific cellular targets.

They also identified targets for potential therapies: bolstering levels of either a particular chaperone or a growth factor in brain cells can protect against the toxic effects of misfolded proteins.

We also develop in silico chemogenomic approaches to analyze jointly the chemical space of small molecules and biological space of protein targets, leading in particular to efficacy profile and secondary effect prediction.

However, the secretion systems» proteins and, in particular, their host targets are largely uncharacterized.

Other theories and lines of research have begun to prosper due to the lack of tangible human results for anti-amyloid immunotherapies, in particular that neurofibrillary tangles of misfolded tau protein are just as much a target for clearance as is amyloid - β, and that perhaps it is time to focus on the decline of known clearance mechanisms rather than the amyloid itself.

The laboratory has a particular focus on neuronal polarity — the structural and functional differences between axons and dendrites — and the mechanisms that underlie polarized targeting of membrane proteins.

In particular, he characterized the first synaptic vesicle membrane associated protein, v - SNARE or VAMP, and the first plasma membrane associated target proteins, t - SNAREs or syntaxin and SNAP - 25.

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

A particular challenge, one that could have important therapeutic applications, is to design an antibody that binds with high affinity to a target protein.

Supplemental pancreatic enzymes (amylase and pancreatin in particular) and supplemental protein - targeting enzymes (known as proteolytic) will reduce the discomfort caused by any Herxheimer (die - off) reactions.

Cats initially selected food based on flavor preferences, but after «learning» (due to prior exposure) about the nutritional composition of the foods, cats selected foods to reach a particular target balance of protein and fat regardless of added flavors.